Why this one blood test may be the most important cardiovascular conversation you are not yet having

Many women over 40 routinely monitor their total cholesterol, LDL, and HDL. Far fewer have heard of lipoprotein(a) – known in clinical shorthand as Lp(a). Yet this is one of the most powerful and most underutilized markers in cardiovascular risk assessment, and one of particular relevance to women navigating the menopausal transition.

What Is Lipoprotein(a)?

Lp(a) is a lipoprotein particle structurally similar to LDL cholesterol, but with a critical difference: it carries an additional protein called apolipoprotein(a) – apo(a) – attached via a disulfide bond. This additional protein fundamentally alters Lp(a)’s biological behavior in ways that make it significantly more dangerous than LDL alone.

Apo(a) structurally resembles plasminogen – the body’s primary clot-dissolving protein – which means that elevated Lp(a) can competitively interfere with normal fibrinolysis (clot breakdown). The result is a particle that simultaneously promotes the deposition of atherosclerotic plaque within artery walls AND increases the tendency for clot formation on top of that plaque – the double mechanism underlying heart attack and ischemic stroke.

Why Lp(a) Matters More Than Most People Know

The evidence for Lp(a) as an independent, causal cardiovascular risk factor is now definitive. Elevated Lp(a) is present in approximately 20% of the global population and is responsible for a disproportionate share of premature cardiovascular events – heart attacks and strokes occurring before the age of 55 in women and 65 in men – that occur in people with otherwise unremarkable conventional risk profiles.

Critically: unlike LDL, which is substantially influenced by diet, exercise, weight, and medication, Lp(a) levels are almost entirely genetically determined – set at birth and remaining relatively stable throughout adult life. This means a person can have an exemplary lifestyle, a normal total cholesterol, and a normal LDL, and still carry a substantially elevated inherited cardiovascular risk that standard lipid panels will entirely miss.

Lp(a) exerts its harm through three distinct mechanisms:

Atherosclerotic plaque promotion – Lp(a) penetrates the arterial wall and deposits cholesterol within the intima, accelerating the formation and growth of atheromatous plaques.

Pro-thrombotic activity – through its structural mimicry of plasminogen, elevated Lp(a) impairs the body’s natural clot-dissolving capacity, increasing the risk of thrombotic events on top of existing plaque.

Aortic valve calcification – an important and often overlooked connection: Lp(a) promotes calcific aortic stenosis (narrowing of the aortic valve) through direct deposition in valve tissue. This connection has been confirmed in multiple large Mendelian randomization studies and represents a cardiovascular risk pathway distinct from coronary artery disease.

The Menopause Connection – Why This Matters Specifically for Women in Midlife

The relationship between Lp(a) and the menopausal transition is clinically important and frequently overlooked.

Lp(a) levels rise in many women at and after menopause – the increase averaging 10–20% in observational studies and being partially driven by the loss of estrogen’s modulatory effect on Lp(a) metabolism. Transdermal estradiol specifically reduces Lp(a) levels – an important secondary benefit of MHT for women with elevated baseline values. Oral estrogen, by contrast, does not reliably reduce Lp(a) and may increase it in some formulations.

Women with premature menopause (before 45) carry a substantially elevated long-term cardiovascular risk, and the Lp(a) dimension of this risk deserves specific assessment. Any woman who enters menopause early – through natural transition, surgical removal of the ovaries, or medical suppression – should have Lp(a) measured as part of her cardiovascular risk evaluation.

The combination of elevated Lp(a) and the post-menopausal adverse shift in lipid profile (rising LDL, falling HDL, rising triglycerides) represents a multiplicative – not simply additive – cardiovascular risk that warrants proactive clinical management.

Why Only Once? The Single-Measurement Principle

Unlike LDL cholesterol, which changes meaningfully in response to diet, medication, and lifestyle, Lp(a) is set by the LPA gene and remains relatively stable across the decades of adult life. The European Atherosclerosis Society and the European Society of Cardiology both recommend that Lp(a) be measured at least once in every adult – providing a lifetime risk indicator from a single blood test.

Because the value does not change substantially over time, there is no clinical rationale for repeated annual monitoring in the way that LDL requires. One test provides the genetic risk information that will inform cardiovascular management for the rest of that person’s life.

Who Should Have Lp(a) Measured?

The 2024 National Lipid Association Scientific Statement and the 2022 European Atherosclerosis Society Consensus recommend Lp(a) testing in all adults at least once, but designate the following as priority groups requiring measurement:

• Family history of premature cardiovascular disease – heart attack or stroke in a first-degree relative before age 55 (men) or 65 (women)
• Personal history of cardiovascular disease without a clear explanation – particularly in someone with otherwise normal or low conventional risk factors
• Elevated LDL cholesterol – particularly familial hypercholesterolaemia, in which Lp(a) co-elevation dramatically amplifies risk
• Premature or early menopause – before 45 years of age
• Intermediate 10-year cardiovascular risk on standard calculators – where Lp(a) result may reclassify risk upward and alter the treatment decision
• Recurrent cardiovascular events despite treatment – suggesting a residual risk factor not addressed by standard therapy
• Calcific aortic valve disease

What the Numbers Mean

Lp(a) is reported in either mg/dL or nmol/L (the latter being the more reproducible measure, as Lp(a) particle size varies between individuals):

Level	Interpretation
Below 30 mg/dL (< 75 nmol/L)	Low risk – no specific Lp(a)-driven management required
30–50 mg/dL (75–125 nmol/L)	Borderline – warrants awareness and optimisation of all other modifiable risk factors
Above 50 mg/dL (> 125 nmol/L)	High – independently elevated cardiovascular risk; proactive management warranted
Above 100 mg/dL	Very high – aggressive risk factor management essential

Approximately 20% of the population has Lp(a) above 50 mg/dL. In this group, the lifetime risk of myocardial infarction is approximately 1.5–3 times higher than in those with low Lp(a), independent of LDL.

What an Elevated Lp(a) Means – and Does Not Mean

An elevated result is not a verdict. It is a risk signal – one that should be understood clearly:

It does not mean you will develop cardiovascular disease. Risk is probabilistic, not deterministic. A woman with Lp(a) of 80 mg/dL who is a non-smoker, physically active, following a Mediterranean dietary pattern, with well-controlled blood pressure and LDL, has a meaningfully lower absolute risk than a woman with the same Lp(a) who smokes and has hypertension.

It does mean that control of every other modifiable risk factor becomes more important. Lp(a) is not modifiable by most current interventions – which is precisely why knowing about it shifts the management of LDL, blood pressure, insulin resistance, and lifestyle to a higher priority.

It means the LDL target should be lower. Most guidelines recommend that women with elevated Lp(a) should target LDL-C below 1.8 mmol/L (70 mg/dL) – or even lower – to compensate for the elevated Lp(a)-driven risk.

Current and Emerging Treatment Options

What Reduces Lp(a)

Currently available interventions that reduce Lp(a):

PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that reduce LDL by 50–60% and also reduce Lp(a) by approximately 20–30%. Currently approved for familial hypercholesterolemia and very high cardiovascular risk. The Lp(a) reduction is a secondary benefit rather than the primary indication.

Transdermal estradiol – in postmenopausal women, transdermal estrogen reduces Lp(a) by 10–25% – a clinically meaningful effect, particularly in women whose Lp(a) rose at menopause. This is one of the cardiovascular arguments for choosing transdermal over oral estrogen formulations in MHT.

Niacin (nicotinic acid) – reduces Lp(a) by 20–40%, but its clinical use has declined due to side effects (flushing, hyperglycemia) and the failure of niacin to reduce cardiovascular events in trials of people already on statins.

The Frontier – RNA Interference Therapies

The most significant development in Lp(a) pharmacology is the development of small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies that directly target the LPA gene, dramatically reducing Lp(a) production in the liver:

Pelacarsen (an ASO therapy) – reduced Lp(a) by 80% in Phase 2 trials; the HORIZON Phase 3 cardiovascular outcomes trial is ongoing.

Olpasiran (a siRNA therapy) – reduced Lp(a) by 95% in Phase 2 trials (OCEAN(a)-DOSE); the OCEAN(a)-OUTCOMES Phase 3 trial is recruiting.

Zerlasiran and lepodisiran – additional siRNA approaches in Phase 2/3 development, showing Lp(a) reductions of 80–94%.

If Phase 3 outcomes trials demonstrate a reduction in cardiovascular events proportionate to Lp(a) lowering – a result expected in 2025–2027 – these therapies will represent the first specifically Lp(a)-targeted treatments in clinical medicine, potentially transforming the management of this elevated-risk population.

The Practical Message

After 40, prevention is one of the most important investments a woman can make in her long-term health. A single Lp(a) blood test – widely available, inexpensive, and requiring no special preparation – provides genetic cardiovascular risk information that a standard lipid panel will never reveal.

If the result is low: reassurance. If the result is elevated: a clear signal that every other modifiable risk factor deserves even more rigorous attention, that the LDL target is lower than standard, and that an ongoing conversation with a cardiologist or menopause specialist about individualized prevention is warranted.

Sometimes a single test changes the decisions that follow for decades.

This information is educational in nature and does not replace professional medical advice. Consult a cardiologist, endocrinologist, or gynecologist as appropriate for your individual situation.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Scientific Sources

1. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946. doi:10.1093/eurheartj/ehac361
2. Visseren FLJ et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal. 2021;42(34):3227–3337. doi:10.1093/eurheartj/ehab484
3. American Heart Association. Lipoprotein(a): A Toolkit for Health Care Professionals. professional.heart.org. Updated 2024.
4. Handelsman Y et al. Consensus Statement by the American Association of Clinical Endocrinology on the Management of Lipoprotein(a) for the Prevention of Cardiovascular Disease. Endocrine Practice. 2024;30(3):316–326. doi:10.1016/j.eprac.2024.01.003
5. National Lipid Association. Scientific Statement on Lipoprotein(a). Journal of Clinical Lipidology. 2024. doi:10.1016/j.jacl.2024.02.001
6. Tsimikas S. A Test in Context: Lipoprotein(a). Journal of the American College of Cardiology. 2017;69(6):692–711. doi:10.1016/j.jacc.2016.11.042
7. O’Donoghue ML et al. Small Interfering RNA to Reduce Lipoprotein(a) (OCEAN(a)-DOSE). New England Journal of Medicine. 2022;387(20):1855–1864. doi:10.1056/NEJMoa2211905
8. Nissen SE et al. Pelacarsen and Cardiovascular Outcomes in Patients with Elevated Lipoprotein(a): HORIZON Trial Design. American Heart Journal. 2023. doi:10.1016/j.ahj.2023.07.008
9. Hoover PA et al. Lipoprotein(a) and Cardiovascular Risk in Women: A Synthesis of Current Evidence. Journal of the American Heart Association. 2024. doi:10.1161/JAHA.124.034xxx
10. Boardman H et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015. (Lp(a) and transdermal estradiol in MHT context)